Bone-targeted Therapies and Radiopharmaceuticals

Bone-targeted Therapies and Radiopharmaceuticals

Daniel Petrylak, MD discusses alpha-emitting isotope therapy and hormonal chemotherapeutic agents and the survival rate of men with CRPC.

Daniel Petrylak, MD
Yale Cancer Center

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe